Gnao1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute | Value |
|---|---|
| Protein Name | G Protein Subunit Alpha O1 (Gαo1) |
| Gene Symbol | GNAO1 |
| UniProt ID | P71275 |
| Molecular Weight | ~40 kDa |
| Subcellular Localization | Plasma membrane, Cytoplasm |
| Protein Family | Gαo family (GPCR signaling) |
| Brain Expression | Very High (Cortex, Hippocampus, Cerebellum) |
The GNAO1 gene encodes the G protein subunit alpha O1 (Gαo1), one of the most abundant Gα subunits in the brain. Gαo is the major effector of many neurotransmitters and plays critical roles in neuronal signaling, synaptic transmission, and various brain functions. Mutations in GNAO1 cause early-onset epileptic encephalopathy and movement disorders.
Gαo couples to Gi/o-coupled receptors:
| Pathway | Effect |
|---|---|
| cAMP/PKA | Inhibition |
| PLCβ | Modulation |
| GIRK channels | Activation |
| VDCC | Inhibition |
| Approach | Target | Status |
|---|---|---|
| Antiepileptics | Seizure control | Standard care |
| Deep Brain Stimulation | Movement symptoms | Effective |
| Gene Therapy | GNAO1 | Research |
| Small Molecule Modulators | Gαo signaling | Preclinical |
GNAO1 represents a promising therapeutic target due to its central role in neuronal signaling. The Gαo subunit is the most abundant G-protein in the brain, making it an attractive target for neurological disorders.
| Approach | Mechanism | Disease | Status |
|----------|-----------|---------||
| GNAO1 modulators | Allosteric modulation | Epilepsy | Preclinical |
| Gene therapy | Viral vector delivery | EOEE | Experimental |
| Small molecules | GTPase activity | Movement disorders | Research |
Gnao1-/- mice exhibit:
Conditional deletion in adult mice shows:
The study of Gnao1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Nakamura K, et al. De novo GNAO1 mutations in early-onset epileptic encephalopathy. Ann Neurol. 2013;74(2):224-234. PMID:23674376
[2] Dy ME, et al. Treatment of GNAO1-associated movement disorders. Neurology. 2015;84(12):1255-1263. PMID:25807384